Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count.
Marion DivouxAlexia PlocqueMargaux SevinLaurent VoillatPierre FeugierAgnès Guerci-BreslerFrancois GirodonJulien BroseusPublished in: Clinical case reports (2020)
Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN-RS-T in the context of major platelet counts.